OINDP Expertise Across UK and US cGMP Facilities
For companies developing Orally Inhaled and Nasal Drug Products (OINDPs), Nanopharm and Aptar Boonton provide critical end-to-end support from early development through to Phase 1 & 2, which are provided in concert with Aptar Pharma’s market-leading device platforms.
Nanopharm - Highlights
- 25,0000 sq ft facility in Wales, UK
- State of the art product development and analytical facility, specialized in OINDPs
- cGMP analytical capabilities for drug, device and drug product release testing
- pMDI, nasal spray, nasal powder, DPI and nebulizer formulation development capabilities
Aptar Boonton - Highlights
- FDA inspected, 32,000 sq ft cGMP facility in New Jersey, USA
- State of the art clinical trial materials (CTM) manufacturing facility with Class 8 clean rooms
- Highly potent API and controlled substances (II-V) suites and handling capabilities
- cGMP manufacturing and fill/finish of dry powders (spray drying and blending), intranasal drug products, and OINDP release and stability testing
Contact Nanopharm
Being part of the Aptar Pharma family ensures a seamless technology transfer and continued access to the full complement of Aptar expertise and capabilities to accelerate and derisk your pathway to the clinic. Having separate sites allows for appropriate processes to be in place to ensure flexible yet robust approaches to meeting your needs, whether in pre-clinical or early clinical development.
